Could a common drug shield kidneys from protein damage?
NCT ID NCT02343094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether sodium phenylbutyrate, a drug already used for other conditions, can reduce a marker of kidney injury in people with proteinuric kidney disease. 26 participants took the drug for 14 days. The goal was to see a 50% drop in a urine marker called Lcn2, which signals kidney stress.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sodium phenylbutyrate
- What this could lead to
- If it works, this could point toward a new treatment to protect kidneys in people with proteinuric kidney disease.
- What could go wrong
- This is a small, early-phase trial with only 26 participants. It measures a lab marker, not long-term kidney health, so success is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk